JP2007537266A - ＩκＢキナーゼ阻害剤として実質的に純粋な２−｛［２−（２−メチルアミノ−ピリミジン−４−イル）−１Ｈ−インドール−５−カルボニル］−アミノ｝−３−（フェニルピリジン−２−イル−アミノ）−プロピオン酸 - Google Patents

ＩκＢキナーゼ阻害剤として実質的に純粋な２−｛［２−（２−メチルアミノ−ピリミジン−４−イル）−１Ｈ−インドール−５−カルボニル］−アミノ｝−３−（フェニルピリジン−２−イル−アミノ）−プロピオン酸 Download PDF

Info

Publication number
JP2007537266A
JP2007537266A JP2007513292A JP2007513292A JP2007537266A JP 2007537266 A JP2007537266 A JP 2007537266A JP 2007513292 A JP2007513292 A JP 2007513292A JP 2007513292 A JP2007513292 A JP 2007513292A JP 2007537266 A JP2007537266 A JP 2007537266A
Authority
JP
Japan
Prior art keywords
compound
ikk
inhibitors
effective amount
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2007513292A
Other languages
English (en)
Japanese (ja)
Inventor
エル−ブダウィ・ハダド
オラーフ・リツェラー
デイヴィッド・ジェイ・オルダス
ポール・ジョゼフ・コックス
Original Assignee
アベンティス・ファーマスーティカルズ・インコーポレイテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アベンティス・ファーマスーティカルズ・インコーポレイテツド filed Critical アベンティス・ファーマスーティカルズ・インコーポレイテツド
Publication of JP2007537266A publication Critical patent/JP2007537266A/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2007513292A 2004-05-12 2005-05-11 ＩκＢキナーゼ阻害剤として実質的に純粋な２−｛［２−（２−メチルアミノ−ピリミジン−４−イル）−１Ｈ−インドール−５−カルボニル］−アミノ｝−３−（フェニルピリジン−２−イル−アミノ）−プロピオン酸 Abandoned JP2007537266A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57014604P 2004-05-12 2004-05-12
PCT/US2005/016381 WO2005113544A1 (en) 2004-05-12 2005-05-11 Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an ikb kinase inhibitor

Publications (1)

Publication Number Publication Date
JP2007537266A true JP2007537266A (ja) 2007-12-20

Family

ID=34969825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007513292A Abandoned JP2007537266A (ja) 2004-05-12 2005-05-11 ＩκＢキナーゼ阻害剤として実質的に純粋な２−｛［２−（２−メチルアミノ−ピリミジン−４−イル）−１Ｈ−インドール−５−カルボニル］−アミノ｝−３−（フェニルピリジン−２−イル−アミノ）−プロピオン酸

Country Status (23)

Country Link
EP (1) EP1747215A1 (es)
JP (1) JP2007537266A (es)
KR (1) KR20070011483A (es)
CN (1) CN1950359A (es)
AR (1) AR049274A1 (es)
AU (1) AU2005245834A1 (es)
BR (1) BRPI0511029A (es)
CA (1) CA2566213A1 (es)
EC (1) ECSP066992A (es)
GT (1) GT200500111A (es)
IL (1) IL178992A0 (es)
MA (1) MA28553B1 (es)
MX (1) MXPA06012870A (es)
NO (1) NO20065719L (es)
PA (1) PA8633101A1 (es)
PE (1) PE20060269A1 (es)
RU (1) RU2006143758A (es)
SV (1) SV2006002111A (es)
TN (1) TNSN06338A1 (es)
TW (1) TW200605881A (es)
UY (1) UY28897A1 (es)
WO (1) WO2005113544A1 (es)
ZA (1) ZA200608712B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE102004033406A1 (de) 2004-07-10 2006-02-16 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
CN104491864A (zh) 2008-04-21 2015-04-08 奥德纳米有限公司 用于治疗耳部疾病和病况的耳用调配物及方法
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2563774B1 (en) * 2010-04-27 2014-03-12 Hutchison Medipharma Limited Pyrimidinyl indole compounds
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3478269A4 (en) 2016-06-29 2020-04-08 Otonomy, Inc. OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES
CN106588803A (zh) * 2016-11-16 2017-04-26 西南科技大学 一种制备5‑乙酰基异噁唑的新方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Also Published As

Publication number Publication date
ECSP066992A (es) 2006-12-29
TNSN06338A1 (en) 2008-02-22
PE20060269A1 (es) 2006-05-11
EP1747215A1 (en) 2007-01-31
AR049274A1 (es) 2006-07-12
RU2006143758A (ru) 2008-06-27
CA2566213A1 (en) 2005-12-11
KR20070011483A (ko) 2007-01-24
GT200500111A (es) 2006-05-09
WO2005113544A1 (en) 2005-12-01
NO20065719L (no) 2006-12-12
MXPA06012870A (es) 2007-02-15
IL178992A0 (en) 2007-03-08
BRPI0511029A (pt) 2007-11-27
SV2006002111A (es) 2006-01-30
ZA200608712B (en) 2008-06-25
TW200605881A (en) 2006-02-16
MA28553B1 (fr) 2007-04-03
UY28897A1 (es) 2005-12-30
AU2005245834A1 (en) 2005-12-01
CN1950359A (zh) 2007-04-18
PA8633101A1 (es) 2006-01-23

Similar Documents

Publication Publication Date Title
JP2007537266A (ja) ＩκＢキナーゼ阻害剤として実質的に純粋な２−｛［２−（２−メチルアミノ−ピリミジン−４−イル）−１Ｈ−インドール−５−カルボニル］−アミノ｝−３−（フェニルピリジン−２−イル−アミノ）−プロピオン酸
JP6841891B2 (ja) 抗炎症化合物としての芳香族複素環化合物
KR101970837B1 (ko) 항바이러스제로서의 피라졸로[1,5-ａ]피리미딘
US9278975B2 (en) Pyrazolo[1,5-A]pyrimidines as antiviral agents
US9745306B2 (en) 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl) quinazolin-4(3H)-one derivatives and their use as phosphoinositide 3-kinase inhibitors
CN110603255B (zh) Jak抑制剂化合物的结晶型式
EP3134410B1 (en) Inhibiting the transient receptor potential a1 ion channel
TW201305185A (zh) 用於抗病毒治療之２’－氟取代之碳－核苷類似物
JP2013542937A (ja) Ｓ−ニトロソグルタチオン還元酵素阻害薬としての新規置換キノリン化合物
CA2826387A1 (en) Method of inhibiting hamartoma tumor cells
US20130005962A1 (en) Process for the synthesis of derivatives of 3-amino-tetrahydrofuran-3-carboxylic acid and use thereof as medicaments
WO2010057877A1 (en) 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
JP2014507453A (ja) １Ｈ−ピロロ［３，２−ｄ］ピリミジンジオン誘導体
US20070142417A1 (en) Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor
JP6441830B2 (ja) カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（シアノ−メチル）−アミド阻害剤
CN115003381A (zh) 化合物及其用于治疗α1-抗胰蛋白酶缺乏症的用途
JPWO2003011812A1 (ja) ヒト−β−トリプターゼ阻害活性を有する新規アミン誘導体およびそれを含有する医薬
KR20220127824A (ko) 알파1-항트립신 결핍의 치료를 위한 4-((2-옥소피리딘-1(2h)-일)메틸)벤즈아미드
JP2023505598A (ja) 化合物及びα１－アンチトリプシン欠損症の治療のためのそれらの使用
JP2012512822A (ja) ピリミジン−２−イルアミノ誘導体および炎症を治療するためのその使用
WO2006076318A1 (en) Monopotassium salt of an ikb kinase inhibitor
CN117337290A (zh) 三并环类泛素特异性蛋白酶1抑制剂及其用途
CN116731022A (zh) 三并环类泛素特异性蛋白酶1抑制剂及其用途
CN117384187A (zh) 泛素特异性蛋白酶1抑制剂
WO2024035771A2 (en) Ulk3 inhibitors and uses thereof

Legal Events

Date Code Title Description
A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20080903